Enrollment is open for a trial of AT2220, a drug designed to enhance the effects of enzyme replacement therapy in people with acid maltase deficiency
New content is being added every day. Please check back again.
Muscular Dystrophy Association — USA National Office222 S. Riverside Plaza, Suite 1500Chicago, IL 60606(800) 572-1717
©2015, Muscular Dystrophy Association Inc. All rights reserved.